Published in J Biol Chem on November 05, 2002
Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest (2006) 3.44
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol (2012) 2.78
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology (2010) 2.10
The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology (2008) 1.90
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther (2008) 1.62
Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev (2014) 1.58
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55
Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal (2010) 1.53
Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. J Hepatol (2012) 1.51
Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther (2011) 1.36
Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther (2008) 1.36
Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep (2011) 1.30
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes (2010) 1.29
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res (2009) 1.27
Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta (2006) 1.26
Melanocortin signaling in the CNS directly regulates circulating cholesterol. Nat Neurosci (2010) 1.25
Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res (2011) 1.17
Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem (2009) 1.14
Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids (2011) 1.09
Sterol regulation of metabolism, homeostasis, and development. Annu Rev Biochem (2011) 1.08
Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol (2010) 1.08
Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. Mol Endocrinol (2010) 1.04
New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol (2006) 1.03
Endocrine and paracrine role of bile acids. World J Gastroenterol (2008) 1.02
Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol (2013) 0.99
Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One (2011) 0.97
Bile acid sequestrants for lipid and glucose control. Curr Diab Rep (2010) 0.96
Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One (2012) 0.96
Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol (2014) 0.94
Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol (2013) 0.94
Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome. J Biol Chem (2011) 0.94
Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol (2008) 0.94
FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol (2009) 0.94
Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res (2010) 0.92
Role of gut microbiota in atherosclerosis. Nat Rev Cardiol (2016) 0.90
Tissue specific induction of p62/Sqstm1 by farnesoid X receptor. PLoS One (2012) 0.90
Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet (2006) 0.89
FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med (2010) 0.89
MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem (2015) 0.88
Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis. Hepat Med (2011) 0.86
Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One (2013) 0.86
New developments in selective cholesteryl ester uptake. Curr Opin Lipidol (2013) 0.85
Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int (2014) 0.85
The extended TILAR approach: a novel tool for dynamic modeling of the transcription factor network regulating the adaption to in vitro cultivation of murine hepatocytes. BMC Syst Biol (2012) 0.84
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. Bioorg Med Chem (2013) 0.83
Identification of genes implicated in methapyrilene-induced hepatotoxicity by comparing differential gene expression in target and nontarget tissue. Environ Health Perspect (2007) 0.82
An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training. Eur J Nutr (2012) 0.82
Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B (2015) 0.81
Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor. J Lipid Res (2011) 0.80
Lipidome in colorectal cancer. Oncotarget (2016) 0.79
Diacylglycerol kinase θ couples farnesoid X receptor-dependent bile acid signalling to Akt activation and glucose homoeostasis in hepatocytes. Biochem J (2013) 0.79
Nuclear receptors in nonalcoholic Fatty liver disease. J Lipids (2011) 0.78
Phospholipase D2 mediates signaling by ATPase class I type 8B membrane 1. J Lipid Res (2012) 0.77
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.77
Effects of alfalfa saponin extract on mRNA expression of Ldlr, LXRα, and FXR in BRL cells. J Zhejiang Univ Sci B (2015) 0.77
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2016) 0.77
Intestinal nuclear receptors in HDL cholesterol metabolism. J Lipid Res (2014) 0.77
Farnesoid X receptor-Acting through bile acids to treat metabolic disorders. Drugs Future (2010) 0.76
Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver. Toxicol Appl Pharmacol (2012) 0.76
The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res (2012) 0.76
Fatty liver diseases, bile acids, and FXR. Acta Pharm Sin B (2016) 0.75
Bile acids reduce endocytosis of high-density lipoprotein (HDL) in HepG2 cells. PLoS One (2014) 0.75
Direct effect of chenodeoxycholic acid on differentiation of mouse embryonic stem cells cultured under feeder-free culture conditions. Biomed Res Int (2012) 0.75
Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) (2016) 0.75
Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver. Acta Pharm Sin B (2016) 0.75
Central melanocortin signaling regulates cholesterol. Nat Neurosci (2010) 0.75
Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. Arterioscler Thromb Vasc Biol (2017) 0.75
Altenusin, a non-steroidal microbial metabolite, attenuates non-alcoholic fatty liver disease by activating the farnesoid X receptor. Mol Pharmacol (2017) 0.75
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol (2004) 3.43
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem (2007) 2.85
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology (2007) 2.11
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res (2005) 1.79
Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab (2010) 1.77
Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos (2008) 1.77
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 1.76
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl) (2005) 1.71
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol (2005) 1.71
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol (2004) 1.70
Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol (2008) 1.69
Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 1.68
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest (2008) 1.68
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med (2013) 1.67
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab (2008) 1.65
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal (2005) 1.64
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol (2007) 1.62
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther (2008) 1.62
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A (2001) 1.61
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem (2002) 1.60
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol (2003) 1.60
Enzymatic mechanisms of ethanol oxidation in the brain. Alcohol Clin Exp Res (2006) 1.59
Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res (2009) 1.59
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology (2008) 1.57
Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol (2006) 1.56
Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes (2011) 1.56